OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the completion of its previously announced merger of OnKure, Inc. and Reneo Pharmaceuticals, Inc. (“Reneo”). The combined company will operate under the name OnKure Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on October 7, 2024 under the ticker symbol “OKUR”.
Read MoreST. LOUIS, Aug. 21, 2024 /PRNewswire/ — Emerson (NYSE: EMR) today announced it has made a strategic investment through its corporate venture capital arm Emerson Ventures in Symmera, an early-stage company simplifying device authentication and data protection. Boulder Ventures will co-invest with Emerson.
Read MoreBoulder, CO – August 20, 2024 – Ambrosia Biosciences Inc. (“Ambrosia” or “the Company”), today announced the successful first closing of its Series A financing. The financing totaled $16 Million and was led by BVF Partners and Boulder Ventures. Ambrosia’s financing will be used to scale up its drug discovery programs and laboratory operations in Boulder, CO.
Read MoreFor Joel Holland, what started as an impulsive decision with his wife to travel the United States in an RV has grown into a business and network that supports over 5,500 small businesses across the country, including a few right in Eagle County.
Read MoreLâle White, CEO of XiFin, wins “CEO of the Year” by San Diego Business Journal for her transformative leadership and significant contributions to the healthcare industry.
Read MoreThis summer, Frasca Food and Wine will celebrate 20 years as one of Colorado's most preeminent restaurants, overseen by wine expert Bobby Stuckey. The establishment, which pairs regional Italian dishes with an 800-bottle wine list, is now one of the state's first restaurants to earn a Michelin star.
Read MoreKendall Clark is the co-founder and CEO of Stardog, a leading enterprise knowledge graph platform with prestigious customers like Morgan Stanley, Raytheon, Bosch, and NASA. He founded the company in 2016 with a vision of making data access more meaningful. Self-taught in coding during his 20s, Kendall is on a mission to help people experience "aha" moments with data more frequently.
Read MoreIRVINE, Calif., and BOULDER, Colo. May 13, 2024 (GLOBE NEWSWIRE) Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors. Upon completion of the transaction, the combined company is expected to operate under the name OnKure Therapeutics, Inc., and trade on the Nasdaq Global Market under the ticker symbol “OKUR”.
Read More
